Cargando…
The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment
Testing for treatment related biomarkers in clinical care, like Ras mutation status in colorectal cancer (CRC), has increased drastically over recent years. Reliable testing of these markers is pivotal for optimal treatment of patients. Participation in external quality assessment (EQA) programs is...
Autores principales: | Dijkstra, Jeroen R., Tops, Bastiaan B. J., Nagtegaal, Iris D., van Krieken, J. Han J. M., Ligtenberg, Marjolijn J. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552773/ https://www.ncbi.nlm.nih.gov/pubmed/26047774 http://dx.doi.org/10.1007/s00428-015-1789-5 |
Ejemplares similares
-
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue
por: Tol, Jolien, et al.
Publicado: (2010) -
RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers
por: Boleij, Annemarie, et al.
Publicado: (2015) -
RAS testing in metastatic colorectal cancer: advances in Europe
por: Van Krieken, J Han JM, et al.
Publicado: (2015) -
EMAST Is Associated with a Poor Prognosis in Microsatellite Instable Metastatic Colorectal Cancer
por: Venderbosch, Sabine, et al.
Publicado: (2015) -
Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice
por: Steeghs, Elisabeth M P, et al.
Publicado: (2022)